FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 54 filers reported holding FATE THERAPEUTICS INC in Q4 2015. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2018 | $1,000 | – | 100 | 0.0% | 0.00% | – |
| Q1 2018 | $0 | -100.0% | 100 | -60.0% | 0.00% | – |
| Q4 2017 | $1,000 | -75.0% | 250 | -80.0% | 0.00% | – |
| Q3 2017 | $4,000 | 0.0% | 1,250 | 0.0% | 0.00% | – |
| Q2 2017 | $4,000 | -20.0% | 1,250 | 0.0% | 0.00% | – |
| Q1 2017 | $5,000 | +25.0% | 1,250 | -28.6% | 0.00% | – |
| Q4 2016 | $4,000 | -60.0% | 1,750 | -46.2% | 0.00% | – |
| Q3 2016 | $10,000 | -23.1% | 3,250 | -58.1% | 0.00% | – |
| Q2 2016 | $13,000 | +85.7% | 7,750 | +93.8% | 0.00% | – |
| Q1 2016 | $7,000 | +133.3% | 4,000 | +300.0% | 0.00% | – |
| Q4 2015 | $3,000 | -25.0% | 1,000 | 0.0% | 0.00% | – |
| Q1 2015 | $4,000 | +33.3% | 1,000 | +42.9% | 0.00% | – |
| Q4 2014 | $3,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |